Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.55 |
| ▸ | GNG2 | P59768 | 1/20 | 0.51 |
| ▸ | GNB1 | P62873 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808028 | 0.85 | GSK3B (0.55) | GSK3BGNG2GNB1PTPN1HPGD | |
| SCHEMBL14357333 | 0.85 | HPGD (0.50) | HPGDMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL30187429 | 0.82 | GSK3B (0.61) | GSK3BPTPN1HPGDMEN1KMT2A | |
| SCHEMBL1726590 | 0.82 | GSK3B (0.61) | GSK3BPTPN1HPGDMEN1KMT2A | |
| SCHEMBL8772648 | 0.81 | HSP90AA1 (0.57) | GSK3BGNG2GNB1PTPN1HPGD | |
| SCHEMBL8647422 | 0.81 | GSK3B (0.50) | GSK3BGNG2GNB1PTPN1HPGD | |
| SCHEMBL4342176 | 0.80 | PTPN1 (0.53) | GSK3BGNG2GNB1PTPN1HPGD | |
| SCHEMBL1232165 | 0.79 | HPGD (0.57) | GSK3BPTPN1HPGDMEN1KMT2A | |
| SCHEMBL29977001 | 0.79 | HPGD (0.57) | GSK3BPTPN1HPGDMEN1KMT2A | |
| SCHEMBL3258577 | 0.79 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | GSK3B 2762/4885GNG2 239/4885GNB1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.